| 1. |
Marlais M, Wlodkowski T, Vivarelli M, et al. The severity of COVID-19 in children on immunosuppressive medication[J/OL]. Lancet Child Adolesc Health, 2020, 4(7): e17-e18[2020-05-13]. https://pubmed.ncbi.nlm.nih.gov/32411815/. DOI: 10.1016/s2352-4642(20)30145-0.
|
| 2. |
Fanlo P, Espinosa G, Adán A, et al. Impact of novel coronavirus infection in patients with uveitis associated with an autoimmune disease: result of the COVID-19-GEAS patient survey[J]. Arch Soc Esp Oftalmol (Engl Ed), 2021, 96(7): 347-352. DOI: 10.1016/j.oftale.2020.12.007.
|
| 3. |
Strangfeld A, Schäfer M, Gianfrancesco MA, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 global rheumatology alliance physician-reported registry[J]. Ann Rheum Dis, 2021, 80(7): 930-942. DOI: 10.1136/annrheumdis-2020-219498.
|
| 4. |
Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry[J]. Ann Rheum Dis, 2020, 79(7): 859-866. DOI: 10.1136/annrheumdis-2020-217871.
|
| 5. |
Zierhut M, De Smet MD, Gupta V, et al. Evolving consensus experience of the IUSG-IOIS-FOIS with uveitis in the time of COVID-19 infection[J]. Ocul Immunol Inflamm, 2020, 28(5): 709-713. DOI: 10.1080/09273948.2020.1780273.
|
| 6. |
Agrawal R, Testi I, Lee CS, et al. Evolving consensus for immunomodulatory therapy in non-infectious uveitis during the COVID-19 pandemic[J]. Br J Ophthalmol, 2021, 105(5): 639-647. DOI: 10.1136/bjophthalmol-2020-316776.
|
| 7. |
Patel A, Kelgaonkar A, Kaza H, et al. Recent advances in diagnosis and treatment of infectious uveitis prevalent in Asia-pacific region[J]. Asia Pac J Ophthalmol (Phila), 2021, 10(1): 99-108. DOI: 10.1097/apo.0000000000000367.
|
| 8. |
Risk M, Hayek SS, Schiopu E, et al. COVID-19 vaccine effectiveness against omicron (B. 1.1. 529) variant infection and hospitalisation in patients taking immunosuppressive medications: a retrospective cohort study[J/OL]. Lancet Rheumatol, 2022, 4(11): e775-e784[2020-08-16]. https://pubmed.ncbi.nlm.nih.gov/35991760/. DOI: 10.1016/s2665-9913(22)00216-8.
|
| 9. |
Kroon FPB, Najm A, Alunno A, et al. Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations[J]. Ann Rheum Dis, 2022, 81(3): 422-432. DOI: 10.1136/annrheumdis-2021-221575.
|
